Robert I. Blum, president and chief executive officer of Cytokinetics (NASDAQ: CYTK), completed sales totaling 36,601 shares of the company’s common stock on March 17, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The transactions were recorded as two separate sales. In the first disposition, Blum sold 12,673 shares. In the second, he sold 23,928 shares. Both transactions were executed at a price of $62.15 per share, producing combined proceeds of $2,274,751.
The Form 4 filing specifies the purpose of the sales as satisfying tax-withholding obligations that arose when restricted stock units vested. The filing does not indicate any other purpose for the transactions.
Following the reported sales, the filing shows multiple lines for Blum’s holdings. It lists direct ownership of 454,258 shares and additionally lists 430,330 shares of Cytokinetics. The filing also shows indirect holdings of 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
Separately, the company has attracted a number of analyst updates in recent weeks that note both clinical milestones and commercial progress:
- Mizuho raised its price target for Cytokinetics to $100, citing an extension of its aficamten intellectual property projection and a higher probability of success for the non-obstructive hypertrophic cardiomyopathy program.
- JPMorgan increased its price target to $75, pointing to a favorable outlook after the approval of Myqorzo for obstructive hypertrophic cardiomyopathy.
- Stifel reiterated a Buy rating and set a $98 price target, assigning a 70% probability of success to the upcoming ACACIA trial.
- Leerink Partners maintained an Outperform rating with an $84 price target, emphasizing the early U.S. launch of Myqorzo and the anticipated ACACIA-HCM Phase 3 readout.
- UBS raised its price target to $69 and now assigns a 50% probability of success for the nHCM program following statistical analysis and discussions with management.
These analyst notes, included in the filing summary, reflect a range of perspectives on Cytokinetics’ programs and commercial potential. The filings do not provide further detail on trading intentions beyond the stated tax-related purpose for the sales.
This report is based on the information contained in the SEC Form 4 filing and the analyst updates as reported. The filing provides exact transaction details and the stated rationale for the disposition; it does not provide additional commentary from the insider or the company about future transactions.